Cover Image

The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis

Objective. The soluble urokinase plasminogen activator receptor (suPAR) is associated with kidney diseases and is used as a prognostic factor of renal function progression. The aim of this study was to explore whether circulating suPAR was associated with antineutrophil cytoplasmic autoantibody- (AN...

Full description

Saved in:

Bibliographic Details
Main Authors:	Fei Huang (Author), Yueqiang Li (Author), Ranran Xu (Author), Anying Cheng (Author), Yongman Lv (Author), Qingquan Liu (Author)
Format:	Book
Published:	Hindawi Limited, 2020-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Serum Soluble Urokinase Plasminogen Activator Receptor Levels in Resistant Hypertension
by: Nergiz Bayrakcı, et al.
Published: (2024)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
by: Dimitrios Velissaris, et al.
Published: (2022)

Detection of soluble urokinase type plasminogen activator receptors in children with gingivitis and normal subjects
by: Mohamed Abd‑Ellatif El‑Patal, et al.
Published: (2022)

Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema
by: Matthias Peter Hilty, et al.
Published: (2016)

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
by: Viktor Rotbain Curovic, et al.
Published: (2022)

Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection
by: Sebastian M. Klim, et al.
Published: (2024)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
by: Ran Zhu, et al.
Published: (2022)

Comment on "Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema"
by: Gaurav Sikri, et al.
Published: (2017)

Soluble urokinase plasminogen activator receptor (suPAR) and glomerular disease in children: a narrative review
by: Phuong Anh Le Thy, et al.
Published: (2022)

Response to: Comment on "Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema"
by: Matthias Peter Hilty, et al.
Published: (2018)

Clinical Value of Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Levels in Term Neonates with Infection or Sepsis: A Prospective Study
by: Tania Siahanidou, et al.
Published: (2014)

Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis
by: Wenjuan Wu, et al.
Published: (2018)

Soluble urokinase-type plasminogen activator receptor as a biomarker for focal segmental glomerulosclerosis; a retrospective analysis
by: Miguel Verdelho, et al.
Published: (2018)

Role of soluble urokinase plasminogen activator receptor in critically ill children with hospital-acquired pneumonia: an observational study in hospital with controls
by: Nagwan Yossery Saleh, et al.
Published: (2024)

Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study
by: Per Lewander, et al.
Published: (2023)

Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue
by: Marianna Sampaio SERPA, et al.
Published: (2018)

Soluble urokinase plasminogen activator receptor in vaginally collected amniotic fluid predicting fetal inflammatory response syndrome: a prospective cohort study
by: Violeta Gulbiniene, et al.
Published: (2024)

Point-of-care prognostication in moderate Covid-19: Analytical validation and prognostic accuracy of a soluble urokinase plasminogen activator receptor (suPAR) rapid test.
by: Arjun Chandna, et al.
Published: (2023)

Point-of-care prognostication in moderate Covid-19: Analytical validation and prognostic accuracy of a soluble urokinase plasminogen activator receptor (suPAR) rapid test
by: Arjun Chandna, et al.
Published: (2023)

Increased Levels of Soluble ST2 in Patients with Active Newly Diagnosed ANCA-Associated Vasculitis
by: Z. Hladinova, et al.
Published: (2015)

Inhibitory effects of wogonin on invasion by human oral cancer cells by decreasing the activity of matrix metalloproteinases and urokinase-plasminogen activator
by: Yung-Chuan Ho, et al.
Published: (2014)

Soluble urokinase plasminogen activator receptor (suPAR) is a potential biomarker of stage III-IV, grade C periodontitis through the impact of post-radiotherapy on head and neck cancer patients
by: Ahmed A. Al-Kubaisi, et al.
Published: (2024)

<i>N</i>-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer
by: Lisa Belfiore, et al.
Published: (2020)

Alteration of the Methylation Status of Urokinase Plasminogen Activator (uPA) is involved in Proliferation and Invasion of Nasopharyngeal Cancer Cells
by: Ju-Hong Yang, et al.
Published: (2015)

Epidemiology of ANCA associated vasculitis
by: Wenche Koldingsnes, et al.
Published: (2008)

Inhibition of urokinase plasminogen activator “uPA” activity alters ethanol consumption and conditioned place preference in mice
by: Al Maamari E, et al.
Published: (2014)

Vasculitis ANCA y esclerosis sistémica
by: Maite Hurtado, et al.
Published: (2016)

Suppression of Urokinase-Type Plasminogen Activator Receptor by Docosahexaenoic Acid Mediated by Heme Oxygenase-1 in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Human Endothelial Cells
by: Sen Lian, et al.
Published: (2020)

ANCA-associated vasculitis following the CoronaVac vaccination
by: Yaohui Ma, et al.
Published: (2022)

ANCA-associated vasculitis in childhood: recent advances
by: Marta Calatroni, et al.
Published: (2017)

Treatment of renal manifestations of ANCA-associated vasculitis
by: Kresimir Galesic, et al.
Published: (2013)

Renal thrombotic microangiopathy in an ANCA-associated vasculitis
by: Ana Teresa Domingos, et al.
Published: (2019)

ANCA Associated Vasculitis Subtypes: Response [Letter]
by: Merkel PA, et al.
Published: (2022)

Neutrophils in ANCA-associated vasculitis: Mechanisms and implications for management
by: Shangqing Ge, et al.
Published: (2022)

Should We Still Use Therapeutic Plasma Exchange for Rapidly Progressive Glomerulonephritis in ANCA Associated Vasculitis?
by: Andre A. Kaplan, et al.
Published: (2022)

TISSUE INHIBITOR OF METALLOPROTEINASE 1, MATRIX METALLOPROTEINASE 9, ALPHA-1 ANTITRYPSIN, METALLOTHIONEIN AND UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR IN SKIN BIOPSIES FROM PATIENTS AFFECTED BY AUTOIMMUNE BLISTERING DISEASES
by: Ana Maria Abreu Velez, et al.
Published: (2013)

Long- term outcome of paediatric patients with ANCA vasculitis
by: Pusey Charles D, et al.
Published: (2011)

Hematoma intraparenquimatoso asociado a vasculitis ANCA positiva
by: Patricia Puerta Roldán, et al.
Published: (2020)

The Prognostic Value of Histopathological Classifications in ANCA-Associated Vasculitis
by: Patrícia Alves, et al.
Published: (2022)

ANCA Associated Vasculitis Subtypes: Response [Response to Letter]
by: Austin K, et al.
Published: (2022)